Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SLRX)

Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program

GlobeNewswire May 14, 2020

Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results

GlobeNewswire May 7, 2020

Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting

GlobeNewswire April 29, 2020

Salarius Pharmaceuticals to Deliver Virtual Presentation at the Emerging Growth Invitational

GlobeNewswire April 22, 2020

Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire March 23, 2020

Salarius Announces Allowance of New European Patent Covering Seclidemstat

GlobeNewswire March 4, 2020

Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference

GlobeNewswire March 2, 2020

Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

GlobeNewswire February 11, 2020

Salarius Pharmaceuticals to Present at the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

GlobeNewswire February 10, 2020

Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

GlobeNewswire February 7, 2020

Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference

GlobeNewswire February 5, 2020

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

GlobeNewswire February 4, 2020

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

GlobeNewswire December 19, 2019

Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

GlobeNewswire December 17, 2019

Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

GlobeNewswire December 16, 2019

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

GlobeNewswire December 12, 2019

Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

GlobeNewswire November 13, 2019

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

GlobeNewswire October 28, 2019

Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

GlobeNewswire October 14, 2019

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children's Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

GlobeNewswire October 8, 2019